- Home
- RDHL vs FBRX Comparison
RDHL vs FBRX Comparison
Compare RDHL & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- FBRX
- Stock Information
- Founded
- RDHL 2009
- FBRX N/A
- Country
- RDHL Israel
- FBRX United States
- Employees
- RDHL N/A
- FBRX N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- FBRX Health Care
- Exchange
- RDHL Nasdaq
- FBRX Nasdaq
- Market Cap
- RDHL 8.6M
- FBRX 8.3M
- IPO Year
- RDHL N/A
- FBRX N/A
- Fundamental
- Price
- RDHL $6.99
- FBRX $18.75
- Analyst Decision
- RDHL
- FBRX Strong Buy
- Analyst Count
- RDHL 0
- FBRX 3
- Target Price
- RDHL N/A
- FBRX $77.58
- AVG Volume (30 Days)
- RDHL 21.2K
- FBRX 1.7M
- Earning Date
- RDHL 12-27-2024
- FBRX 11-14-2024
- Dividend Yield
- RDHL N/A
- FBRX N/A
- EPS Growth
- RDHL N/A
- FBRX N/A
- EPS
- RDHL N/A
- FBRX N/A
- Revenue
- RDHL $3,707,000.00
- FBRX N/A
- Revenue This Year
- RDHL $224.90
- FBRX N/A
- Revenue Next Year
- RDHL $82.69
- FBRX N/A
- P/E Ratio
- RDHL N/A
- FBRX N/A
- Revenue Growth
- RDHL N/A
- FBRX N/A
- 52 Week Low
- RDHL $6.35
- FBRX $4.11
- 52 Week High
- RDHL $43.50
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- RDHL 42.91
- FBRX 52.67
- Support Level
- RDHL $7.09
- FBRX $18.33
- Resistance Level
- RDHL $7.44
- FBRX $24.64
- Average True Range (ATR)
- RDHL 0.53
- FBRX 3.23
- MACD
- RDHL -0.03
- FBRX -0.99
- Stochastic Oscillator
- RDHL 12.36
- FBRX 8.56
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).